Arcus Biosciences, Inc. Operating Cash Flow
Arcus Biosciences, Inc. (RCUS) reported Operating Cash Flow of -$257.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-05
- Arcus Biosciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$119.00M.
- Arcus Biosciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$138.00M.
- Arcus Biosciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$120.00M.
- Arcus Biosciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$97.00M, a 473.08% decline year-over-year.
- Arcus Biosciences, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$482.00M.
- Arcus Biosciences, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$170.00M.
- Arcus Biosciences, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$306.00M, a 169.86% decline from fiscal 2022.
- Arcus Biosciences, Inc. net cash provided by (used in) operating activities for fiscal 2022 was $438.00M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$119.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$257.00M 10-Q · filed 2026-08-05 | -$377.00M derived: sum of 3 quarters · filed 2026-08-05 | -$474.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | -$138.00M 10-Q · filed 2026-05-05 | -$258.00M derived: sum of 2 quarters · filed 2026-05-05 | -$355.00M derived: sum of 3 quarters · filed 2026-05-05 | -$488.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | -$120.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$217.00M derived: sum of 2 quarters · filed 2026-02-25 | -$350.00M derived: sum of 3 quarters · filed 2026-08-05 | -$482.00M 10-K · filed 2026-02-25 | ||||
| 2025-09-30 | -$97.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | -$230.00M derived: sum of 2 quarters · filed 2026-08-05 | -$362.00M 10-Q · filed 2025-10-28 | -$462.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | -$133.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$265.00M 10-Q · filed 2026-08-05 | -$365.00M derived: sum of 3 quarters · filed 2026-08-05 | -$339.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | -$132.00M 10-Q · filed 2026-05-05 | -$232.00M derived: sum of 2 quarters · filed 2026-05-05 | -$206.00M derived: sum of 3 quarters · filed 2026-05-05 | -$300.00M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | -$100.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$74.00M derived: sum of 2 quarters · filed 2026-02-25 | -$168.00M derived: sum of 3 quarters · filed 2026-02-25 | -$170.00M 10-K · filed 2026-02-25 | ||||
| 2024-09-30 | $26.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | -$68.00M derived: sum of 2 quarters · filed 2025-10-28 | -$70.00M 10-Q · filed 2025-10-28 | -$158.00M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-06-30 | -$94.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$96.00M 10-Q · filed 2025-08-06 | -$184.00M derived: sum of 3 quarters · filed 2026-02-25 | -$247.00M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-03-31 | -$2.00M 10-Q · filed 2025-05-06 | -$90.00M derived: sum of 2 quarters · filed 2026-02-25 | -$153.00M derived: sum of 3 quarters · filed 2026-02-25 | -$210.00M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2023-12-31 | -$88.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$151.00M derived: sum of 2 quarters · filed 2026-02-25 | -$208.00M derived: sum of 3 quarters · filed 2026-02-25 | -$306.00M 10-K · filed 2026-02-25 | ||||
| 2023-09-30 | -$63.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$120.00M derived: sum of 2 quarters · filed 2024-11-06 | -$218.00M 10-Q · filed 2024-11-06 | -$288.00M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-06-30 | -$57.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$155.00M 10-Q · filed 2024-08-08 | -$225.00M derived: sum of 3 quarters · filed 2025-02-25 | -$306.00M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-03-31 | -$98.00M 10-Q · filed 2024-05-08 | -$168.00M derived: sum of 2 quarters · filed 2025-02-25 | -$249.00M derived: sum of 3 quarters · filed 2025-02-25 | -$314.00M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2022-12-31 | -$70.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$151.00M derived: sum of 2 quarters · filed 2025-02-25 | -$216.00M derived: sum of 3 quarters · filed 2025-02-25 | $438.00M 10-K · filed 2025-02-25 | ||||
| 2022-09-30 | -$81.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$146.00M derived: sum of 2 quarters · filed 2023-11-07 | $508.00M 10-Q · filed 2023-11-07 | $507.74M 10-Q · filed 2022-11-02 | $446.07M derived: sum of 4 quarters · filed 2024-02-21 | |||
| 2022-06-30 | -$65.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $589.00M 10-Q · filed 2023-08-07 | $588.70M 10-Q · filed 2022-08-03 | $527.07M derived: sum of 3 quarters · filed 2024-02-21 | $473.31M derived: sum of 4 quarters · filed 2024-02-21 | |||
| 2022-03-31 | $654.00M 10-Q · filed 2023-05-09 | $654.00M 10-Q · filed 2022-05-09 | $592.07M derived: sum of 2 quarters · filed 2024-02-21 | $538.31M derived: sum of 3 quarters · filed 2024-02-21 | $464.32M derived: sum of 4 quarters · filed 2024-02-21 | |||
| 2021-12-31 | -$61.93M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | -$115.69M derived: sum of 2 quarters · filed 2024-02-21 | -$189.68M derived: sum of 3 quarters · filed 2024-02-21 | -$256.00M 10-K · filed 2024-02-21 | -$256.17M 10-K · filed 2022-02-23 | |||
| 2021-09-30 | -$53.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | -$127.75M derived: sum of 2 quarters · filed 2022-11-02 | -$194.07M 10-Q · filed 2022-11-02 | -$244.12M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-06-30 | -$74.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$140.31M 10-Q · filed 2022-08-03 | -$190.36M derived: sum of 3 quarters · filed 2023-02-28 | $25.90M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-03-31 | -$66.32M 10-Q · filed 2022-05-09 | -$116.37M derived: sum of 2 quarters · filed 2023-02-28 | $99.90M derived: sum of 3 quarters · filed 2023-02-28 | $75.96M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2020-12-31 | -$50.05M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $166.22M derived: sum of 2 quarters · filed 2023-02-28 | $142.28M derived: sum of 3 quarters · filed 2023-02-28 | $111.00M 10-K · filed 2023-02-28 | $111.17M 10-K · filed 2021-02-25 | |||
| 2020-09-30 | $216.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $192.33M derived: sum of 2 quarters · filed 2021-11-08 | $161.05M 10-Q · filed 2021-11-08 | $151.58M derived: sum of 4 quarters · filed 2022-02-23 | ||||
| 2020-06-30 | -$23.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$55.22M 10-Q · filed 2021-08-05 | -$64.69M derived: sum of 3 quarters · filed 2022-02-23 | -$92.08M derived: sum of 4 quarters · filed 2022-02-23 | ||||
| 2020-03-31 | -$31.28M 10-Q · filed 2021-05-05 | -$40.75M derived: sum of 2 quarters · filed 2022-02-23 | -$68.15M derived: sum of 3 quarters · filed 2022-02-23 | -$87.90M derived: sum of 4 quarters · filed 2022-02-23 | ||||
| 2019-12-31 | -$9.47M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | -$36.87M derived: sum of 2 quarters · filed 2022-02-23 | -$56.62M derived: sum of 3 quarters · filed 2022-02-23 | -$73.46M 10-K · filed 2022-02-23 | ||||
| 2019-09-30 | -$27.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$47.15M derived: sum of 2 quarters · filed 2020-11-05 | -$63.99M 10-Q · filed 2020-11-05 | -$71.10M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-06-30 | -$19.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$36.59M 10-Q · filed 2020-08-06 | -$43.70M derived: sum of 3 quarters · filed 2021-02-25 | -$55.46M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-03-31 | -$16.84M 10-Q · filed 2020-05-05 | -$23.95M derived: sum of 2 quarters · filed 2021-02-25 | -$35.71M derived: sum of 3 quarters · filed 2021-02-25 | -$46.59M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2018-12-31 | -$7.11M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$18.87M derived: sum of 2 quarters · filed 2021-02-25 | -$29.75M derived: sum of 3 quarters · filed 2021-02-25 | -$43.00M 10-K · filed 2021-02-25 | ||||
| 2018-09-30 | -$11.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | -$22.64M derived: sum of 2 quarters · filed 2019-11-05 | -$35.89M 10-Q · filed 2019-11-05 | -$20.30M derived: sum of 4 quarters · filed 2019-11-05 | ||||
| 2018-06-30 | -$10.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$24.12M 10-Q · filed 2019-08-06 | -$8.54M derived: sum of 3 quarters · filed 2019-08-06 | -$32.77M derived: sum of 4 quarters · filed 2019-08-06 | ||||
| 2018-03-31 | -$13.25M 10-Q · filed 2019-05-02 | $2.34M derived: sum of 2 quarters · filed 2019-05-02 | -$21.89M derived: sum of 3 quarters · filed 2019-05-02 | -$28.71M derived: sum of 4 quarters · filed 2019-05-02 | ||||
| 2017-12-31 | $15.59M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-05 | -$8.65M derived: sum of 2 quarters · filed 2019-03-05 | -$15.46M derived: sum of 3 quarters · filed 2019-03-05 | -$25.06M 10-K · filed 2019-03-05 | ||||
| 2017-09-30 | -$24.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$31.05M derived: sum of 2 quarters · filed 2018-11-08 | -$40.65M 10-Q · filed 2018-11-08 | |||||
| 2017-06-30 | -$6.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | -$16.41M 10-Q · filed 2018-08-06 | ||||||
| 2017-03-31 | -$9.60M 10-Q · filed 2018-05-09 | |||||||
| 2016-12-31 | -$12.94M 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |